Our Expertise Is Synthetic DNA



  • Targeted resequencing
  • Virus
  • Pathogens
  • Metagenomics


  • Pathogen mode of action
  • Non-coding DNA
  • RNA editing


  • Gene synthesis
  • Genome synthesis
  • Biofuel & chemical production
  • Directed evolution


  • Antibodies
  • Vaccines
  • shRNA
  • Antibiotics


  • Ultra long-term
  • No power
  • High density



Emily Leproust, PhD

Chief Executive Officer

As an early pioneer in long DNA synthesis, Emily is poised to accelerate the biofactory market. She and co-founder Bill Peck share the world record for synthesizing the longest, highest quality oligo library. Emily architected the successful SureSelect product line which lowered the cost of sequencing and elucidated dozens of mendelian diseases, and she developed Agilent’s Oligo Library Synthesis technology. Emily has co-authored over 34 peer-reviewed papers—many on synthetic DNA—and has extensive marketing, management, and business development experience. Prior to Twist Bioscience, Emily was Director of Applications and Chemistry R&D—Genomics at Agilent Technologies.

View Publications

Bill Banyai, PhD

Chief Operating Officer

Bill is a seasoned entrepreneur and silicon engineering expert. He has been a founder or first employee at four different start-ups and advises early stage startups. As VP of hardware engineering at Complete Genomics, he built their sequencing technology and delivered three generations of human genome chips and sequencers. Bill has twice been awarded multi-million dollar DARPA grants for the development of innovative technologies based on silicon micro machining. Bill’s career spans research, product development, and semiconductor device processing. He holds a PhD in Optical Sciences from the University of Arizona, an MS in Electrical Science from University of Michigan, and served as Staff Physicist at Lawrence Livermore National Laboratory.

View Publications

Bill Peck, PhD

Chief Technology Officer

Bill Peck is an expert in managing difficult technology projects and delivering robust scalable biological manufacturing processes. At Complete Genomics he developed sequencer fluidics systems, including silicon nano-array flowcell, and oversaw instrument integration into Human Genome Sequencing Factory. At Agilent, Bill architected two generations of their high density microarray manufacturing platforms. In addition to his experience in chemical process automation and hardware development, Bill’s technical expertise is in nanofluidics with original research in birth evolution and decay of turbulence created by droplets. As a post-doc fellow at Stanford/NASA-Ames, Bill researched computational fluid mechanics and developed a numerical code to model free surface flows.

View Publications

Solange Glaize

Chief Financial Officer

Solange has an extensive Fortune 500 company experience leading financial and operational teams globally. Throughout her career, she has been instrumental in building finance and infrastructure capabilities, and in enabling business strategic development and international expansion. Prior to Twist Bioscience, she served as Vice President, Corporate Controller and Chief Accounting Officer for Agilent Technologies, where she was responsible for the entire accounting function, SOX compliance, and external statutory reporting. Before, Solange served as the Life Sciences Group (LSG) operational CFO and also headed the LSG’s business development organization. She joined Agilent with the spin-off from Hewlett-Packard and served as Managing Director of European Financial Services in Brussels, Belgium. She transferred in 2001 to the Bay Area and subsequently held several finance controller roles, including Commercial Controller of the Semiconductor Products Group and Manufacturing Controller for the Life Sciences and Chemical Analysis Group. Solange began her career with Hewlett Packard, where she held a variety of escalating finance and managerial roles both in Europe and the United States. She obtained her MS in Management from HEC School of Management in Paris, France.


Patrick Finn

Vice President of Sales and Marketing

Patrick has a strong track record of high-growth sales in bioreagent, B2B and custom manufacturing organizations. His technical background paired with his ability to identify customer's unmet needs make him the ideal fit to lead our commercial organization. Before Twist Bioscience, Paddy served as Vice President of Sales and Marketing for Enzymatics (recently acquired by QIAGEN), leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers. Prior to Enzymatics, Paddy held positions with increasing commercial focus, including Director of Business Development at Agilent Technologies, Director of Product Development for Beckman Coulter Molecular Diagnostics, and multiple technical roles in product development within Invitrogen and GE Healthcare/Amersham International. In addition, Paddy currently serves on the Scientific Advisory Board of Lasergen and previously served on the Scientific Advisory Board of Enzymatics. He holds a PhD in Nucleic Acid Chemistry from Southampton University and a BSc Hons in Chemistry from Heriot-Watt University.


Patrick Weiss

Vice President of Operations

Patrick is a diversified and well rounded executive and serial entrepreneur with a wide range of experience in building, integrating and managing businesses across diverse market segments. His detailed understanding of highly technical manufacturing work flows and products is complemented by a proven track record of successfully creating organizations, product lines, technologies and processes to maximize performance. Prior to Twist Bioscience, Patrick consulted for a wide range of life science companies both to build start-up organizations and execute turnarounds. Previously, he served as President and CEO of Operon Biotechnologies Inc., a global leader of DNA synthesis services, where he turned around the business from net loss to profitability in a short period of time. He restructured the business, eventually negotiating a successful merger with Eurofins SA. Prior to Operon, he founded Xeragon, an international provider of RNA synthesis and bioinformatics products (now QIAGEN). Patrick received his MSc in Organic Chemistry, Analytical Chemistry, Molecular Biology, Genetics and Economics from the Swiss Federal Institute of Technology. He is an author of several issued patents.

Our Investors

ARCH Venture Partners

ARCH Venture Partners, one of the largest early stage technology venture firms in the U.S., invests in the development of seed and early stage advanced technology companies that have the potential to grow rapidly into successful businesses. ARCH enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions, corporate research groups and national laboratories. ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 150 companies. Our limited partners include major corporations, pension funds, university endowments, financial institutions, and private investors

Paladin Capital Group

Paladin Capital Group is a leading multi-stage private equity firm that provides funding to growing companies. Across the globe, from Silicon Valley to Brazil, we invest in best-of-breed companies with technologies, products, and services that meet the challenging demands of commercial, federal, and international customers. Paladin has over $950 million of committed capital invested across multiple funds.

Making DNA in Mission Bay,
San Francisco’s biotech

455 Mission Bay Blvd South
San Francisco, CA